#USA #Singapore #Emerald Clinical #Glenn Kerkhof #Mary Gunn

Emerald Clinical Trials Announces Leadership Transition

Emerald Clinical Trials, a leading global clinical research organization, has declared a notable shift in its leadership as Mary Gunn steps down from her role as CEO, effective immediately. The board of directors has appointed Glenn Kerkhof, a long-standing board member and seasoned executive in clinical research, as the interim CEO.

This transition comes at a critical time, with the board's official search for a permanent CEO already underway. Glenn Kerkhof, leveraging his extensive experience in the clinical research field, is set to guide the organization during this transitional phase. He aims to maintain continuity, stability, and robust execution of Emerald's operations.

Sean Carney, the board chair, expressed gratitude for Mary Gunn's contributions to the organization and voiced confidence in Kerkhof’s ability to steer the company forward. Carney stated, "Emerald Clinical Trials is a leading clinical research organization with global capabilities. With Glenn as our interim CEO, we are confident in our ability to build on our momentum and meet our clients' expectations."

Glenn Kerkhof brings over 30 years of extensive experience in both clinical research and pharmaceutical services. Prior to his interim appointment, Kerkhof was the CEO of Chiltern, where he successfully led the company during a significant international expansion. He also served as executive chairman of George Clinical, the predecessor to Emerald Clinical Trials, where he played a pivotal role in its growth across Asia.

In his new role, Kerkhof emphasized that Emerald Clinical's strengths lie in its therapeutic focus, scientific depth, and close partnerships with clients. He stated, "I will focus on ensuring a seamless transition, delivering quality services to our clients, and supporting our international teams. I am committed to continuing our trajectory and leading with clarity and determination."

About Emerald Clinical Trials

Emerald Clinical Trials is a premier clinical research organization offering comprehensive trial services globally. Serving over a hundred biotechnology companies and six of the ten largest pharmaceutical organizations, the Singapore-based company is recognized for its operational expertise and scientific excellence. It provides robust solutions for all phases of clinical trials, ensuring exceptional service to its worldwide clients. For further information, visit www.emeraldclinical.com.

Conclusion

As Emerald Clinical Trials navigates this leadership transition, the focus remains on strengthening client relationships and maintaining operational excellence. The board's proactive measures signal a commitment to stability and quality, setting the stage for continued success in the clinical research landscape.